Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

Introduction Blood cancer diagnostics refers to the process of detecting and identifying cancers that affect the blood, bone marrow, and lympha ...

The potential impact of this form of therapy in pediatric precursor B-lineage acute lymphoblastic leukemia ... tested in patients with non-Hodgkin's lymphoma (NHL), but not in patients with ...

adding to its earlier approvals for diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukaemia. Kymriah was the first CAR-T to reach the market in 2017, but was closely followed by ...

The Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas ... cleared for use in acute lymphoblastic lymphoma (ALL).

Incyte (NASDAQ:INCY – Free Report) had its price objective hoisted by Stifel Nicolaus from $75.00 to $77.00 in a report released on Monday morning,Benzinga reports. Stifel Nicolaus currently has a ...

The cells are in B-cell Lym-phoblastic lymphoma are indistinguishable from those seen in lymphoblastic leukemia. Following this patient was referred to us at Medical Oncology Department. On ...

R Squared Ltd bought a new position in shares of Incyte Co. (NASDAQ:INCY – Free Report) in the fourth quarter, ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.

For a school going child with thalassemia juggling the stress of monthly checkpoints with the hassle of monthly transfusions, the possibility of a permanent cure for the chronic condition is a ray of ...